Myriad Genetics ( NASDAQ: MYGN ) announced a collaboration with GSK aimed at improving access to homologous recombination deficiency diagnostic testing for high-grade serous ovarian cancer patients. A new sponsored testing program leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudi Arabia, Singapore, and United Arab Emirates. Source: Press Release More on Myriad Genetics Myriad Genetics, Inc.
(MYGN) Q1 2024 Earnings Call Transcript Myriad Genetics surges 17% as Street applauds 2024 guidance, Q1 results Myriad Genetics GAAP EPS of -$0.29 beats by $0.01, revenue of $202.
2M beats by $8.95M Seeking Alpha’s Quant Rating on Myriad Genetics Historical earnings data for Myriad Genetics.
